Communicate with Supplier? Supplier
Kelly Ms. Kelly
What can I do for you?
Chat Now Contact Supplier

 Shandong Haohong Biotechnology Co., Ltd.

All
  • All
  • Title
All
  • All
  • Title
  • Hot Products

About Us

Shandong Haohong Biotechnology Co., Ltd. is located in Provincial Chemical Industrial Park of Liaocheng city, Shandong province, which is a beautiful water city. The total production area is around 130 thousand square meters, with 40 employees and 12 R&D technicians. Our company focuses on the development and production of pharmaceutical products, with 13 sets of 50L to 5000L reactors, and the annual manufacturing capacity can up to 500 tons. We had advanced sewage treatment system, with the daily processing capacity of 1000 tons. The new R&D laboratory is located on the 4th floor of the accelerator middle section of Qilu Science and Technology Town, Qilu High-tech Development Zone, Shandong Province, and is located in a large modern ecological science and technology park in Qihe Science and Technology City of Zhongguancun Haidian Park. Our company mainly focuses on the development of anti-cancer, anti-diabets series of API and its advanced intermediates. The main products include Bicalutamide, enzalutamide, apalutamide, macitentan, cabozantinib, ceritinib, empagliflozin, tofacitinib citrate, and alectinib,etc. In line with the concept of "truth-seeking, innovation and integrity", we had exported our products to the United States, European countries, Japan, India, Bangladesh and other overseas markets. At present, Our company has dozens of advanced intermediates, all of which are commercialized, and at the same time, we can provide customers with efficient customized synthesis services from grams to 100 kilograms. We will continue to provide high quality products with most competitive prices and good service to customers all over the world. We sincerely hope to establish stable and strategic business relationships with customers from home and abroad. Welcome to visit our website: www.haohongtech.com www.haohongpharma.com

  • New Products

News Center

  • Enzalutamide or abiraterone?

    April 01, 2021

    Enzalutamide and abiraterone are both types of hormone therapy that treat advanced prostate cancer. Your hospital doctor will talk to you about which drug is most suitable for you. For example, enzalutamide may be a better option than abiraterone if your cancer has spread to the liver or lungs, or if you can`t take steroids. Abiraterone must be taken with a steroid. But abiraterone may be a better option than enzalutamide if you`ve had: any falls any seizures (fits) or you have an increased risk of seizures extreme tiredness (fatigue) problems with memory or concentration. This is because enzalutamide can increase your risk of these problems. Some men may find enzalutamide easier to take because, unlike abiraterone, you don`t need to take it on an empty stomach and you don`t need to take steroids. But some men want to avoid the tiredness that enzalutamide can cause, and prefer to take abiraterone. Speak to your doctor or specialist nurse about which treatments might be suitable for you and when to have them. You can also talk things through with our Specialist Nurses. Other health problems and medicines Tell your doctor if you have any heart or kidney problems. Enzalutamide may not be suitable for you if you`ve had seizures, a stroke or injury to your brain in the past, or if the cancer has spread to your brain. Enzalutamide may affect ho

  • Enzalutamide

    April 01, 2021

    Enzalutamide (Xtandi) is a type of hormone therapy for men with prostate cancer that has spread to other parts of the body (advanced prostate cancer). It is usually only offered to men whose prostate cancer has stopped responding to other types of hormone therapy. But during the coronavirus outbreak, you may be offered enzalutamide as a first treatment for advanced prostate cancer. Enzalutamide works by blocking the effect of the hormone testosterone on prostate cancer cells. Without testosterone, the prostate cancer cells can`t grow, even if they have spread to other parts of the body. Enzalutamide has been shown to help some men live longer. It can also help to treat or delay symptoms, such as pain and bone problems. Who can have enzalutamide? Enzalutamide is a treatment for advanced prostate cancer. It is most commonly offered to men whose cancer has stopped responding to other types of hormone therapy. You may hear this called hormone-relapsed or castrate-resistant prostate cancer. You can have enzalutamide before or after chemotherapy. Your hospital doctor may offer you enzalutamide if you can`t have chemotherapy, or you don`t want to have it yet. Enzalutamide may be suitable if your cancer isn`t causing any symptoms or only mild symptoms. You may be offered enzalutamide if you`ve had a chemotherapy drug called docetaxel and your cancer has stopped responding to it. If you`ve alre

  • Alcohol and Cancer Risk: Clinical and Research Implications

    April 01, 2021

    Ample evidence has been available for some time indicating that alcohol use is a preventable risk factor for cancer, and the World Health Organization deemed alcohol a carcinogen more than 30 years ago. In the United States, it is estimated that 5.6% of incident cancer cases (approximately 87 000 each year) are associated with alcohol, including cancers of the oral cavity, pharynx, larynx, liver, esophagus (squamous cell carcinoma), female breast, and colorectum.1 Type of alcohol does not appear to matter; all alcoholic beverages include ethanol, which increases levels of acetaldehyde and in turn promotes DNA damage. Moreover, even moderate levels of consumption (often defined as approximately 14-28 g/d, the equivalent of about 1-2 drinks) appear to be associated with higher risk of some cancers, including cancers of the female breast.2 A protective association has emerged for some cancers, with the most evidence for kidney, Hodgkin lymphoma, and non-Hodgkin lymphoma.2 Nonetheless, the overall cancer burden associated with alcohol use is substantial and comparable with that of other preventable risk factors such as UV exposure and excess body weight. Ecological studies examining trends in alcohol consumption along with cancer incidence and mortality rates suggest that decreases in alcohol intake may reduce cancer risk. One analysis of data from 17 countries showed that changes in cancer mortality rates for alcohol-related cancers tended to parallel changes in per capita annual alcohol sales 7 to 9

  • A common cold virus may help fight COVID-19

    April 01, 2021

    A lab-based study has found that a virus that causes the common cold can trigger an innate immune response against SARS-CoV-2, the virus responsible for COVID-19. In theory, infections with the common cold virus could inhibit the transmission of SARS-CoV-2 among members of a population and reduce the severity of infections. Further research could lead to control strategies or treatments that exploit such interactions between viruses. For decades, scientists have been hunting for a cure for the common cold, with little success. However, recent research hints that this bothersome - though usually mild - infection may be a hidden ally in the fight against pandemic viruses such as influenza and SARS-CoV-2. Human rhinoviruses (HRVs), which cause more than half of all common colds, are the most widespread respiratory viruses in humans. Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment. Previous researchTrusted Source suggests that HRVs may have inhibited the spread of the influenza A virus subtype H1N1 across Europe during the 2009 flu pandemic. Experts believe that the HRVs did this by inducing human cells to produce interferon, which is part of the body`s innate immune defenses against viral infection. Research has shown that SARS-CoV-2 is susceptibleTrusted Source to the effects of interferon. This finding led scientists at the MRC-University of Glasgow Centre for Virus Research in the United Kingdom to speculate whether HRVs could help combat the spread of SARS-CoV-2 and limit the severity of infections. Human respiratory cells To find out, the researchers infected cultures of human respiratory cells in the lab with either SARS-CoV-2, an HRV, or both viruses at the same time. The cultures closely mimicked the outer layer

Send Inquiry Now

Home

Phone

About Us

Inquiry